Opportunity Information: Apply for RFA DA 12 001
Apply for RFA DA 12 001
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "New Molecular Entities to Treat Substance Use Disorders (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Dec 22, 2010 and posted on Dec 22, 2010.
- Applicants must submit their applications by Mar 17, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Eligible applicants include: City or township governments County governments Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities For profit organizations other than small businesses Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Native American tribal governments (Federally recognized) Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Private institutions of higher education State governments.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity "New Molecular Entities to Treat Substance Use Disorders (R01)" (Funding Opportunity Number RFA-DA-12-001) was issued by the National Institutes of Health (NIH) through the National Institute on Drug Abuse (NIDA). It is a discretionary, R01 research grant aimed specifically at supporting preclinical projects that can move quickly from early drug discovery into the early stages of development. The central purpose is to speed the identification and validation of new molecular entities (NMEs) as promising candidate compounds, with a longer-term, translational emphasis on advancing those candidates toward eventual FDA approval as safe and effective medications for treating substance use disorders (SUDs). In practical terms, the opportunity is designed to fund work that bridges the often slow and fragmented path between finding a novel compound and generating the early development evidence needed to justify further investment and progression toward clinical testing.
The focus on "accelerated pace" and "drug discovery to early development" signals that NIDA was looking for projects with a clear, execution-ready plan to advance candidate molecules through key preclinical milestones. While the announcement summary is brief, the intent is typical of translational medication development initiatives: applicants are expected to propose research that does more than basic target exploration, instead emphasizing actionable steps such as identifying novel compounds, optimizing lead candidates, demonstrating efficacy in relevant preclinical models, characterizing mechanism of action, and generating foundational data needed for development decisions. The end goal is to produce NMEs that are not just interesting scientifically, but realistically positioned to move forward as medication candidates for SUDs, an area where treatment needs remain significant.
The program was cataloged under CFDA 93.279 (Drug Abuse and Addiction Research Programs) and did not require cost sharing or matching. NIDA estimated total funding at $2,000,000 for the initiative. Because this is an R01 mechanism, it generally supports discrete, hypothesis-driven or milestone-driven research projects led by an independent investigator or team, and it often allows enough flexibility to combine multiple complementary workstreams (for example, medicinal chemistry plus in vivo efficacy testing plus early safety or pharmacokinetic profiling) as long as the proposal remains cohesive and strongly justified.
Eligibility for this funding opportunity was broad and included many types of domestic and non-domestic entities. Eligible applicants listed in the source data include state governments; county, city, township, special district governments; federally recognized and other tribal governments and tribal organizations; U.S. territories or possessions; public and private institutions of higher education; independent school districts; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (other than institutions of higher education); for-profit organizations (including small businesses and for-profits other than small businesses); and other categories referenced in the announcement. Additional eligible groups explicitly mentioned include Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, foreign (non-U.S.) organizations, and eligible federal government agencies. This wide eligibility range reflects an intention to draw innovation from academia, industry, and mission-driven organizations, including groups with specialized capabilities in chemistry, pharmacology, toxicology, or translational development.
Key administrative details from the posting indicate the opportunity was posted and created on December 22, 2010, with an original and current closing date of March 17, 2011, and an archive date of April 17, 2011. There is a public link to the full funding announcement hosted on the NIH grants site (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-001.html). For technical access or linking issues, the contact provided is the NIH Office of Extramural Research (OER) Webmaster via FBOWebmaster@OD.NIH.GOV.
Overall, this R01 was positioned as a translational preclinical drug discovery and early development funding opportunity with a clear deliverable: advancing new molecular entities toward becoming viable medication candidates for substance use disorders. It emphasizes speed and practical development progression, encouraging applicants to propose research plans that reduce the gap between initial discovery and the kind of evidence package that can support later-stage development and, ultimately, FDA review.
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The opportunity is titled "New Molecular Entities to Treat Substance Use Disorders (R01)."
What is the funding opportunity number?
The Funding Opportunity Number is RFA-DA-12-001.
Which agency issued this opportunity?
This opportunity was issued by the National Institutes of Health (NIH) through the National Institute on Drug Abuse (NIDA).
What type of grant mechanism is this?
This is an NIH R01 research grant (a discretionary research project grant).
What is the main purpose of this R01?
The central purpose is to speed the identification and validation of new molecular entities (NMEs) as promising candidate compounds for treating substance use disorders (SUDs), with a longer-term translational emphasis on advancing candidates toward eventual FDA approval as safe and effective medications.
Is this opportunity focused on basic research or translational research?
It is positioned as translational, preclinical drug discovery and early development research. The emphasis is on bridging the gap between early discovery of a compound and the early development evidence needed to justify further investment and potential progression toward clinical testing.
What stage of research is this opportunity intended to support?
The opportunity is aimed specifically at preclinical projects that can move quickly from early drug discovery into the early stages of development.
What does "accelerated pace" mean in the context of this announcement?
Based on the description, "accelerated pace" signals that NIDA was looking for projects with a clear, execution-ready plan to advance candidate molecules through key preclinical milestones, rather than open-ended basic exploration.
What kinds of activities or workstreams are implied as a good fit?
The description indicates an expectation for actionable, development-oriented steps such as identifying novel compounds, optimizing lead candidates, demonstrating efficacy in relevant preclinical models, characterizing mechanism of action, and generating foundational data used for development decisions.
What is meant by "new molecular entities (NMEs)" here?
In this opportunity, NMEs refers to new candidate compounds intended to become medications for substance use disorders, with the goal of identifying and validating them as realistic candidates for further development.
What is the longer-term goal of the funded work?
The longer-term goal is to advance promising candidate compounds toward eventual FDA approval as safe and effective medications for treating substance use disorders.
Is the program tied to a specific CFDA number?
Yes. The program was cataloged under CFDA 93.279 (Drug Abuse and Addiction Research Programs).
Is cost sharing or matching required?
No. The posting states that cost sharing or matching was not required.
How much total funding did NIDA estimate for this initiative?
NIDA estimated total funding at $2,000,000 for the initiative.
Who is eligible to apply?
Eligibility was broad and included a wide range of domestic and non-domestic entities, including various levels of government, tribal governments and organizations, U.S. territories or possessions, public and private institutions of higher education, independent school districts, public housing authorities/Indian housing authorities, nonprofits (with and without 501(c)(3) status, other than institutions of higher education), for-profit organizations (including small businesses and other for-profits), and other categories referenced in the announcement.
Are foreign (non-U.S.) organizations eligible?
Yes. Foreign (non-U.S.) organizations were explicitly mentioned as eligible.
Are minority-serving institutions included in eligibility?
Yes. The eligibility list explicitly includes Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations were explicitly mentioned as eligible.
Are federal government agencies eligible to apply?
Yes. Eligible federal government agencies were listed among eligible applicants.
When was the opportunity posted?
The posting indicates it was posted and created on December 22, 2010.
What was the application closing date?
The original and current closing date shown in the posting is March 17, 2011.
When was the opportunity archived?
The archive date provided is April 17, 2011.
Where can applicants find the full funding announcement?
The full announcement is available on the NIH grants site at: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-12-001.html
Who should be contacted for technical access or linking issues?
For technical access or linking issues, the contact provided is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What is the practical problem this program is trying to solve?
The program is designed to address the often slow and fragmented path between discovering a novel compound and generating the early development evidence needed to justify continued investment and progression toward clinical testing.
What kind of outcomes is NIDA looking for from funded projects?
The described deliverable focus is advancing NMEs to become viable medication candidates for substance use disorders by producing preclinical and early development evidence that supports development decisions and later-stage progression.
Does the opportunity emphasize single-project focus or multiple integrated activities?
Because it uses the R01 mechanism, it generally supports discrete projects led by an independent investigator or team, and it can allow multiple complementary workstreams (for example, medicinal chemistry plus in vivo efficacy testing plus early safety or pharmacokinetic profiling) as long as the proposal is cohesive and well justified.
Browse more opportunities from the same category: Education Health
Next opportunity: Fund Arizona Fish and Game Department to Collect and Rear the Endangered Humpback Chub (Gila cypha)
Previous opportunity: Rural Innovation Fund Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 12 001
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 12 001) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploring Human Induced Pluripotent Stem Cells for Substance Abuse Research (R21) Apply for RFA DA 11 012 Funding Number: RFA DA 11 012 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Personalized Genomics for Symptom Management Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R01) Apply for RFA NR 11 003 Funding Number: RFA NR 11 003 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Personalized Genomics for Symptom Management Bridging the Gaps from Genomic Discovery to Improved Health Outcomes (R21) Apply for RFA NR 11 004 Funding Number: RFA NR 11 004 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Acute Life Threatening Conditions and Opportunities for Palliative and End of Life Care Research (R01) Apply for RFA NR 11 008 Funding Number: RFA NR 11 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Interdisciplinary Approaches for HIV/AIDS Risk Avoidance Decision Making in Developing Adolescents (R01) Apply for RFA NR 11 007 Funding Number: RFA NR 11 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Alzheimers Disease Pilot Clinical Trials (R01) Apply for PAR 11 100 Funding Number: PAR 11 100 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| U.S. India Bilateral Brain Research Collaborative Partnerships (U.S. India BRCP) (R21) Apply for PAR 11 099 Funding Number: PAR 11 099 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Increasing Opportunities in Advanced Heart Failure and Palliative Care Research (R01) Apply for RFA NR 11 006 Funding Number: RFA NR 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Reducing Health Disparities Among Minority and Underserved Children (R01) Apply for PA 11 104 Funding Number: PA 11 104 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Reducing Health Disparities Among Minority and Underserved Children (R21) Apply for PA 11 105 Funding Number: PA 11 105 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Lasker Clinical Research Scholars Program (SI2) Apply for RFA OD 11 001 Funding Number: RFA OD 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Pre Application for the 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02) Apply for PAR 11 102 Funding Number: PAR 11 102 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2011 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 11 009 Funding Number: RFA DA 11 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization (R44) Apply for RFA CA 11 002 Funding Number: RFA CA 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Predictive Animal Models for Smoking Cessation Medications (U54) Apply for RFA DA 11 014 Funding Number: RFA DA 11 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Centers for AIDS Research and Developmental Centers for AIDS Research (P30) Apply for PAR 11 108 Funding Number: PAR 11 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance Related Disorders (U01) Apply for PAR 11 109 Funding Number: PAR 11 109 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 11 111 Funding Number: PA 11 111 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NINR Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows In Nursing Research (F31) Apply for PAR 11 117 Funding Number: PAR 11 117 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Specific pathogen free macaque colonies (U42) Apply for PAR 11 116 Funding Number: PAR 11 116 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 12 001", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.